Pillar Pacific Capital Management LLC Sells 350 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Pillar Pacific Capital Management LLC trimmed its stake in United Therapeutics Co. (NASDAQ:UTHR) by 9.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,525 shares of the biotechnology company’s stock after selling 350 shares during the period. Pillar Pacific Capital Management LLC’s holdings in United Therapeutics were worth $589,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of UTHR. Signaturefd LLC grew its stake in United Therapeutics by 17.5% in the 1st quarter. Signaturefd LLC now owns 362 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 54 shares during the period. Parallel Advisors LLC grew its stake in United Therapeutics by 15.1% in the 1st quarter. Parallel Advisors LLC now owns 679 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 89 shares during the period. JJJ Advisors Inc. grew its stake in United Therapeutics by 38.0% in the 1st quarter. JJJ Advisors Inc. now owns 338 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 93 shares during the period. Cardinal Capital Management grew its stake in United Therapeutics by 1.7% in the 1st quarter. Cardinal Capital Management now owns 6,706 shares of the biotechnology company’s stock valued at $1,122,000 after acquiring an additional 110 shares during the period. Finally, Los Angeles Capital Management LLC grew its stake in United Therapeutics by 1.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 8,273 shares of the biotechnology company’s stock valued at $1,256,000 after acquiring an additional 125 shares during the period. 90.09% of the stock is owned by hedge funds and other institutional investors.

NASDAQ UTHR opened at $193.77 on Friday. The company has a market cap of $8.68 billion, a P/E ratio of 18.33 and a beta of 0.52. The company has a debt-to-equity ratio of 0.24, a current ratio of 7.22 and a quick ratio of 6.88. The stock has a 50-day moving average of $195.06 and a two-hundred day moving average of $164.39. United Therapeutics Co. has a 1-year low of $98.37 and a 1-year high of $212.62.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 5th. The biotechnology company reported $0.61 EPS for the quarter, missing the Zacks’ consensus estimate of $2.60 by ($1.99). United Therapeutics had a return on equity of 15.48% and a net margin of 33.25%. The company had revenue of $379.10 million for the quarter, compared to analyst estimates of $368.31 million. During the same period in the prior year, the firm posted $3.61 earnings per share. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Co. will post 12.55 EPS for the current fiscal year.

A number of research firms recently issued reports on UTHR. LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $151.00 to $199.00 and gave the company a “buy” rating in a research note on Wednesday, January 20th. Credit Suisse Group raised their price objective on United Therapeutics from $169.00 to $196.00 and gave the company an “outperform” rating in a report on Monday, March 1st. Wedbush raised their price objective on United Therapeutics from $255.00 to $260.00 and gave the company an “outperform” rating in a report on Thursday, February 25th. They noted that the move was a valuation call. HC Wainwright lifted their price target on United Therapeutics from $195.00 to $248.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, TheStreet lowered shares of United Therapeutics from a “b” rating to a “c+” rating in a report on Wednesday. Seven investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $227.14.

In related news, Director Judy D. Olian sold 2,103 shares of the company’s stock in a transaction that occurred on Wednesday, March 17th. The stock was sold at an average price of $170.00, for a total value of $357,510.00. Following the completion of the transaction, the director now directly owns 7,893 shares of the company’s stock, valued at $1,341,810. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Judy D. Olian sold 4,207 shares of the company’s stock in a transaction that occurred on Thursday, April 1st. The shares were sold at an average price of $184.96, for a total value of $778,126.72. Following the completion of the transaction, the director now directly owns 9,997 shares of the company’s stock, valued at $1,849,045.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,410 shares of company stock valued at $1,154,689. Corporate insiders own 10.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More: Understanding dividend yield and dividend payout ratio

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.